Imagen de Portada

Pharmacoeconomical analysis of the use of upadacitinib, baricitinib and dupilumab for systemic therapy of patients with moderate and severe atopic dermatitis

Objective. Comparative pharmacoeconomic evaluation of upadacitinib, baricitinib and dupilumab for the treatment of moderate to severe atopic dermatitis.Materials and methods. Study design - retrospective. Pharmacoeconomic analysis method - cost-eﬀectiveness analysis, budget impact analysis. Data sou...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	S. K. Zyryanov (Autor), I. N. Dyakov (Autor), N. I. Ilina (Autor)
Formato:	Libro
Publicado:	Izdatelstvo OKI, 2023-07-01T00:00:00Z.
Materias:	article
Acceso en línea:	Connect to this object online.
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
por: Celeste M. Boesjes, et al.
Publicado: (2023)

Efficacy of dupilumab in moderate and severe atopic dermatitis
por: Stephan Weidinger, et al.
Publicado: (2023)

Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
por: Miguel Nogueira, et al.
Publicado: (2021)

Efficacy of Upadacitinib and Dupilumab on Achieving Stringent and Composite Skin and Itch Outcomes: an Indirect Comparison of Adults with Moderate-to-Severe Atopic Dermatitis
por: April W. Armstrong, et al.
Publicado: (2024)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
por: Novin Nezamololama, et al.
Publicado: (2020)

Efficacy of baricitinib 4 mg in patients with moderate‐to‐severe atopic dermatitis previously treated with systemic therapy
por: Antonio Costanzo, et al.
Publicado: (2023)

Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan
por: Teppei Hagino, et al.
Publicado: (2023)

Pharmacoeconomic analysis of using biological agents for uncontrolled moderate-to-severe atopic asthma in the Russian Federation
por: S. K. Zyryanov, et al.
Publicado: (2020)

Effectiveness and safety of upadacitinib in patients with face and neck atopic dermatitis unresponsive to dupilumab
por: Yan Yang, et al.
Publicado: (2023)

More Time Spent with Clear Skin and No Itch with Upadacitinib versus Dupilumab for Atopic Dermatitis
por: Andrew Blauvelt, et al.
Publicado: (2024)

Dupilumab in patients with moderate to severe atopic dermatitis and multiple sclerosis
por: Maria Esposito, MD, et al.
Publicado: (2023)

Effectiveness and Safety of Upadacitinib in Combination with Topical Corticosteroids in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis
por: Hagino T, et al.
Publicado: (2023)

Efficacy of tralokinumab after failure with upadacitinib and dupilumab in a patient affected by atopic dermatitis
por: L. Mastorino, et al.
Publicado: (2023)

Efficacy and Safety of Upadacitinib for Management of Moderate-to-Severe Atopic Dermatitis: An Evidence-Based Review
por: Yuliya Lytvyn, et al.
Publicado: (2022)

Effect of abrocitinib and dupilumab on eosinophil levels in patients with moderate‐to‐severe atopic dermatitis
por: Delphine Staumont‐Sallé, et al.
Publicado: (2023)

Is Dupilumab a chance for patients with moderate to severe atopic dermatitis? Literature review
por: Paweł Iwańczuk
Publicado: (2024)

Baricitinib for atopic dermatitis patients who responded inadequately to dupilumab treatment: First daily practice results
por: Linde deWijs, et al.
Publicado: (2022)

Immediate exacerbation of atopic dermatitis after switching from upadacitinib to dupilumab: A report of two cases
por: Makoto Ito, et al.
Publicado: (2023)

Sustained Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A 48-Week Real-World Study
por: Teppei Hagino, et al.
Publicado: (2024)

Remission of severe atopic dermatitis with dupilumab and rescue tofacitinib therapy
por: Danielle M. Peterson, MD, et al.
Publicado: (2021)

harmacoeconomic feasibility of using the drug upadacitinib in patients with rheumatoid arthritis in the healthcare system of the Russian Federation
por: A. M. Lila, et al.
Publicado: (2020)

Targeted Combined Endpoint Improvement in Patient and Disease Domains in Atopic Dermatitis: A Treat-to-Target Analysis of Adults with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib
por: Shawn G. Kwatra, et al.
Publicado: (2024)

Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis
por: Jonathan I. Silverberg, et al.
Publicado: (2021)

Influence of dupilumab on the economic burden of severe asthma and atopic dermatitis
por: I. S. Krysanov, et al.
Publicado: (2020)

Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis
por: Awosika O, et al.
Publicado: (2018)

Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series
por: Adrien Mareschal, et al.
Publicado: (2020)

Baricitinib provides rapid and sustained improvements in absolute EASI and SCORAD outcomes in adults with moderate-to-severe atopic dermatitis
por: Jacob P. Thyssen, et al.
Publicado: (2023)

Successful Treatment with Upadacitinib of Patient with Persistent Head and Neck Atopic Dermatitis Refractory to Dupilumab: A Case Report
por: So Yun Park, et al.
Publicado: (2024)

Observational 24‐week study to assess clinical response to upadacitinib posttrial in patients with moderate‐to‐severe atopic dermatitis
por: Ana Batalla, et al.
Publicado: (2023)

Pharmacoeconomic comparison of the second generation insulin analogs and insulins on their base
por: I. N. Dyakov, et al.
Publicado: (2021)

Pharmacoeconomic effectiveness of lenvatinib in patients with differentiated radioiodine-resistant thyroid cancer
por: S. K. Zyryanov, et al.
Publicado: (2018)

Efficacy and safety of dupilumab in adult moderate-to-severe atopic dermatitis: An update narrative literature review
por: Magdalini Kreouzi, et al.
Publicado: (2022)

Pharmacoeconomic characteristics of agonists of receptors for glucagon-like peptide-1 and medicines on their base
por: I. N. Dyakov, et al.
Publicado: (2021)

Pharmacoeconomic comparison of insulin glargine and insulin detemir in diabetes mellitus type 2
por: I. N. Dyakov, et al.
Publicado: (2020)

Pharmacoeconomic analysis of the use of a fixed combination of tiotropium bromide and olodaterol as maintenance therapy in patients with chronic obstructive pulmonary disease in the Russian Federation
por: S. К. Zyryanov, et al.
Publicado: (2022)

Biologic Therapy of Moderate and Severe Forms of Atopic Dermatitis in Children
por: Nikolay N. Murashkin, et al.
Publicado: (2020)

Onychodystrophy associated with dupilumab therapy for atopic dermatitis
por: Amanda E. Zubek, MD, PhD, et al.
Publicado: (2021)

Dupilumab as a combination therapy to oral systemic immunomodulators for moderate-to-severe atopic dermatitis for skin of color children in resource-limited setting: A case series
por: Siti Nuraihan, et al.
Publicado: (2023)

Real‐world effectiveness and safety of dupilumab in patients with moderate and severe atopic dermatitis: 2‐year experience
por: Chisako Fujiwara, et al.
Publicado: (2023)

Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
por: Teppei Hagino, et al.
Publicado: (2024)